The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid in a sealed vial |
| Solubility class | Soluble in water and polar organic solvents | Reconstituted solutions are generally clear |
| Typical storage temperature | -20 degrees Celsius or below, dry | Protect from light; avoid repeated freeze-thaw cycles |
| Common analytical methods | Reversed-phase HPLC-UV, LC-MS | Used for purity estimation and mass confirmation |
| Reported purity range | Area percentage above 95 percent | Reporting practice and acceptance limits differ by laboratory |
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
== Imaging findings == Most cases of SRIF are not detectable clinically (clinically occult), and have no visible abnormalities on chest CT. In clinically occult cases, a range of findings have been described on CT, including no abnormalities, low attenuation areas, clustered cysts with visible walls, and ground-glass opacities with or without reticulation. In symptomatic patients, the radiologic features described on chest computed tomograms (chest CT, or CT scans of the chest) include bilateral ground-glass opacities (haziness in both lungs) and emphysema without reticulation, traction bronchiectasis or honeycombing.
== International presence == Viscofan exports a large part of its products to other markets and is currently present in over 100 countries. It has production centers in 13 countries and maintains commercial offices in 15 countries.
== Awards == German Innovation Award. Excellence in Business to Business – Pharmaceuticals, Winner 2019 German Innovation Award, Fortibone January 2020 Nutra Ingredients Awards. Ingredient of the Year: Healthy Ageing – Fortibone, GELITA – 2018, Winner 2018, January 2020 Life PR Award: German Innovation Award in gold for innovative detergent additive Novotec CB800, June 6, 2018 Nutraceuticals World: Top 100 Innovative Companies in Germany, Category "Innovative Processes" Cannes Corporate Media & TV Awards 2016: Four Dolphins for the company Video "You can see". Gold in category corporate videos and silver in the categories marketing films – B2B, information films and visitors films German Brand Award for successful brand management in the category "Industry Excellence in Branding", 2016 "Intermedia-globe Award" in gold, World Media Festival June 22, 2016 Frost & Sullivan Award, "European Health Ingredient of the Year" – 2008 New Hope, "GELITA Wins Frost & Sullivan Award European Health Ingredient of the Year 2008"
=== Sony Computer Entertainment === In 1997, Ueda joined Sony Computer Entertainment Japan. He began work on Ico, being granted his own unit as the studio had little experience in developing games on their own (mostly the Ape Escape series) due to their focus on assisting third-party developers. After Ico, Ueda and his small team started work on Shadow of the Colossus. In February 2007, Japanese gaming magazine Famitsu reported that Ueda and his team were working on a game for the PlayStation 3. No details about the unnamed title were revealed. In 2008, in the August edition of PlayStation Magazine, Sony Worldwide Studios boss Shuhei Yoshida commented that both Ico and Shadow of the Colossus took 4 years to develop as a hint that the game was under production, but was not close to release. The game was revealed at E3 2009 as The Last Guardian, the trailer for which suggests a saga involving elements of both Ico and Shadow of the Colossus wherein a young boy resembling Ico partners up with a colossus-sized companion to complete puzzles. Ueda later confirmed The Last Guardian to be related to the two previous installments. In an interview with G4tv.com in 2009 he expressed admiration for the method of cut-scene story-telling in Valve's Half-Life 2, and when questioned directly expressed an interest in making a first-person game.
Sources: en.wikipedia.org
=== Abuse of LGBTQ+ people === According to Amnesty International on 9 February 2024, two Houthi-run courts in Yemen sentenced 48 individuals either to death, flogging, or prison over charges related to same-sex conduct in the past month.
Prevention trials look for ways to prevent disease in people who have never had the disease or to prevent a disease from returning. These approaches may include drugs, vitamins or other micronutrients, vaccines, or lifestyle changes. Screening trials test for ways to identify certain diseases or health conditions. Diagnostic trials are conducted to find better tests or procedures for diagnosing a particular disease or condition. Treatment trials test experimental drugs, new combinations of drugs, or new approaches to surgery or radiation therapy. Quality of life trials (supportive care trials) evaluate how to improve comfort and quality of care for people with a chronic illness. Genetic trials are conducted to assess the prediction accuracy of genetic disorders making a person more or less likely to develop a disease. Epidemiological trials have the goal of identifying the general causes, patterns or control of diseases in large numbers of people. Compassionate use trials or expanded access trials provide partially tested, unapproved therapeutics to a small number of patients who have no other realistic options. Usually, this involves a disease for which no effective therapy has been approved, or a patient who has already failed all standard treatments and whose health is too compromised to qualify for participation in randomized clinical trials. Usually, case-by-case approval must be granted by both the FDA and the pharmaceutical company for such exceptions.
Enzymes are generally globular proteins, acting alone or in larger complexes. The sequence of the amino acids specifies the structure which in turn determines the catalytic activity of the enzyme. Although structure determines function, a novel enzymatic activity cannot yet be predicted from structure alone. Enzyme structures unfold (denature) when heated or exposed to chemical denaturants and this disruption to the structure typically causes a loss of activity. Enzyme denaturation is normally linked to temperatures above a species' normal level; as a result, enzymes from bacteria living in volcanic environments such as hot springs are prized by industrial users for their ability to function at high temperatures, allowing enzyme-catalyzed reactions to be operated at a very high rate. Enzymes are usually much larger than their substrates. Sizes range from just 62 amino acid residues, for the monomer of 4-oxalocrotonate tautomerase, to over 2,500 residues in the animal fatty acid synthase. Only a small portion of their structure (around 2–4 amino acids) is directly involved in catalysis: the catalytic site. This catalytic site is located next to one or more binding sites where residues orient the substrates. The catalytic site and binding site together compose the enzyme's active site. The remaining majority of the enzyme structure serves to maintain the precise orientation and dynamics of the active site. In some enzymes, no amino acids are directly involved in catalysis; instead, the enzyme contains sites to bind and orient catalytic cofactors.
Sources: en.wikipedia.org
Vascular EDS (vEDS; formerly categorized as type 4) is identified by skin that is thin, translucent, extremely fragile, and bruises easily. It is also characterized by fragile blood vessels and organs that can easily rupture. Affected people are frequently short and have thin scalp hair. It also has characteristic facial features, including large eyes, an undersized chin, sunken cheeks, a thin nose and lips, and ears without lobes. Joint hypermobility is present, but generally confined to the small joints (fingers, toes). Other common features include club foot, tendon and/or muscle rupture, acrogeria (premature aging of the skin of the hands and feet), early-onset varicose veins, pneumothorax (collapse of a lung), the recession of the gums, and a decreased amount of fat under the skin. It can be caused by the variations in the COL3A1 gene. Rarely, COL1A1 variations can also cause it.
Such designers included Dave McDermott, who initially ran the Sven Co-op website before becoming a developer of it. Fearon had planned from the onset to include support for cooperatively playing through Half-Life's single-player campaign within Sven Co-op, but this was hampered initially by how the game's engine transitions from map to map, and made it difficult to keep players together in the multiplayer approach. Ultimately, the team was able to work this out, and later added support for Half-Life's two expansions, Half-Life: Opposing Force, and Half-Life: Blue Shift. Around 2004, prior to the release of Half-Life 2, Fearon had been planning to release Sven Co-op on Steam, but didn't due to confusion between the Sven Co-op team and Valve. Further, Fearon and the team had started work on a Sven Co-op 2 in anticipation of using the Source engine from Half-Life 2. Though they had developed a large number of assets for the mod, they were hindered by the lack of the SDK, which had been pushed back along with the release of Half-Life 2. Many of the team members had started to move on to other projects, and Fearon found they lost too many key members to continue development. Around this point Fearon opted to leave the project, giving the project lead over to Josh Polito. McDermott and Polito began negotiations with Valve to gain access to the GoldSrc engine around 2010 and to have Valve change some of the numerical limits originally imposed in the engine's use in Half-Life that would enable them to improve Sven Co-op.
=== Recurring === Dave Franco as Danny Wegbriet, Yoshi's shifty, stoner, childhood friend, who usually ends up making things worse when Yoshi turns to him for help. He notably wears some sort of new hat in each of his appearances. Michaela Dietz as Hannah Schwooper, Avi and Jen's daughter. Born in 2009, she is technically not Jewish as her mother is not and Avi did not raise her around the culture due to his own disassociation from religion. In middle school Hannah has a good relationship with her father and shares his interests but is isolated from children her own age, though she does find a friend group at the end of "Wolves". She is passionate about photography, and also has a strained relationship with Jen after her and her father divorce. She grows more interested in her Jewish heritage adound this time as well, though fears she is not "Jewish enough" to do so. Gina Rodriguez as Rachel "Baby" Feldstein, Shira's bisexual childhood best friend. The two began secretly hooking up during their senior year of high school, with Shira genuinely having feelings for but Baby acting dodgey about having a conversation about their relationship. In 2002, Shira sneaks out of her mom’s ceremony to prom to make things official but she catches Rachel kissing a boy. During their ensuring argument she discovers Rachel never saw their relationship as anything more than a mindless fling, and a heartbroken Shira angrily ends their relationship, though Rachel callously retorted back they never had anything, further devastating Shira.
==== Reliance on industry giants ==== Training frontier AI models requires an enormous amount of computing power. Usually only Big Tech companies have the financial resources to make such investments. Smaller start-ups such as Cohere and OpenAI end up buying access to data centers from Google and Microsoft respectively.
Sources: en.wikipedia.org
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.
Most certificates state a percentage derived from chromatographic peak area, alongside a mass confirmation. The exact criteria and acceptance thresholds vary between laboratories.
Dry powder is kept frozen or refrigerated and protected from light and moisture. Solutions are handled cold and used promptly to limit degradation.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.